7
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Is There a Role for MACOP-B in the Treatment of Diffuse Large Cell Lymphoma?

&
Pages 85-89 | Published online: 01 Jul 2009

References

  • Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann. Intern. Med. 1985; 102: 596
  • Weick J. K., Dahlberg S., Fisher R. I., Dana B., Miller T. P., Balcerzak S. P., Pierce H. I. Combination chemotherapy of intermediate-grade and high-grade non-Hodg-kin's lymphoma with MACOP-B: A Southwest Oncology Group Study. J. Clin. Oncol. 1991; 9: 748–753
  • Shipp M., Harrington D., Anderson J., Armitage J., Bonadonna G., Brittinger G., Cabanillas F., Canellos G., Coiffier B., Connors J., Cowan R., Crowther D., Engelhard M., Fisher R., Gisselbrecht C., Horning S., Lepage E., Lister A., Meerwaldt J., Montserrat E., Nis-sen N., Oken M., Peterson B., Tondini C., Velasquez W., Yeap B. Development of a predictive model for aggressive lymphoma: The international NHL prognostic factors poject. Proc. Am. Soc. Clin. Oncol., (abstract) 1992; 319
  • Carbone P. P., Kaplan H. S., Musshoff K., et al. Report of the Committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860
  • National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112
  • Hoskins P. J., Ng V., Spinelli J., Klimo P., Connors J. M. Prognostic variables in patients with diffuse large cell lymphoma treated with MACOP-B. J. Clin. Oncol. 1991; 9: 220
  • Klimo P., Connors J. M. Updated clinical experience with MACOP-B. Sem. Hematol. 1987; 24(suppl)26
  • Coltman C. A., Jr., Dahlberg S., Jones S. E., . CHOP is curative in thirty percent of patients with large cell lymphoma: A twelve year Southwest Oncology Group follow-up. Update on Treatment for diffuse large cell lymphoma, A. T. Skarin, et al. John Wiley & Sons, New York 1986; 71–7
  • Longo D. L., DeVita V. T., Duffey P. L., Wesley M. N., Ihde D. C., Hubbard S. M., et al. Superiority of ProMACE Cytabom over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J. Clin. Oncol. 1991; 25: 9
  • Skarin A. T., Canellos G. P., Rosenthal D. S., et al. Moderate dose methotrexate (m) combined with bleomycin (B), Adriamycin (A), cyclophosphamide (C), Oncovin (O), and dexamethasone (D), m-BACOD in advanced diffuse histiocytic lymphoma (DHL). Proc. Am. Soc. Clin. Oncol. 1983; 2: 200, (abstract)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.